A recent study published in the journal Clinical Infectious Disease has found a potential link between cannabis use and possible beneficial reduction in systemic inflammation and immune activation in HIV-infected individuals being treated with antiretroviral therapy (ART).
It turns out that heavy cannabis use—defined by plasma quantity of THC-COOH—was associated with decreased frequencies of activated T cells and inflammatory antigen-presenting cell subsets, which suggests a potential immunologic benefit of cannabinoids through decreased immune activation in HIV-infected individuals.
“The novel finding is important given that elevated levels of T-cell activation have been associated with lower CD4+ T-cell gains following ART and with mortality in this population,” study authors write. “Thus, our work suggests that cannabinoids may have an immunological benefit in the context of HIV infection, as lowering the frequency of activated T cells could limit the risk of development of non-AIDS-associated comorbidities.”
Study authors sought to determine the impact of cannabis